Скачать или смотреть Intravitreal Implant Extends Treatment Duration for Wet AMD, with Avni Finn, MD

During #ASRS2025, we sat down with Avni Finn, MD, associate professor of ophthalmology, vitreoretinal diseases, and surgery at Vanderbilt Eye Institute, to discuss the positive results from the DAVIO 2 trial. EYP-1901, an investigative intravitreal implant for the treatment of wet age-related macular degeneration, has shown noninferiority to aflibercept - so much so that a single dose resulted in better treatment outcomes than a Q8W aflibercept program.

“Our patients with wet macular degeneration are elderly, they have trouble getting to appointments, they oftentimes need somebody to accompany them to appointments, which means somebody else has to take a day off work to bring them in. Putting in something that is sustained release and can really give patients more durability…it’s really going to change the burden of coming in for regular visits, for regular injections.”

Highlights
00:00 Intro
00:32 Why choose aflibercept over a treat-and-extend protocol?
01:04 Why did the study include only previously treated eyes?
02:16 How could EYP-1901 change patient management in settings where adherence is a challenge?
03:24 Do you see any baseline characteristics that might identify early responders?
03:57 How does EYP-1901 compare with other implants like the Port Delivery System?
04:40 How do you see EYP-1901 fitting into the wet AMD treatment algorithm?

https://www.hcplive.com/view/eyp-1901...

#AMD #ophthalmology #eyecare